Crystal and solution structures of human oncoprotein Musashi‐2 N‐terminal RNA recognition motif 1
View/ Open
Issue Date
2019-10-29Author
Lan, Lan
Xing, Minli
Kashipathy, Maithri
Douglas, Justin
Gao, Philip
Battaile, Kevin
Hanzlik, Robert P.
Lovell, Scott
Xu, Liang
Publisher
Wiley
Type
Article
Article Version
Scholarly/refereed, author accepted manuscript
Rights
© 2019 The Authors. Proteins: Structure, Function, and Bioinformatics published by Wiley Periodicals, Inc.
Metadata
Show full item recordAbstract
Musashi‐2 (MSI2) belongs to Musashi family of RNA binding proteins (RBP). Like Musashi‐1 (MSI1), it is overexpressed in a variety of cancers and is a promising therapeutic target. Both MSI proteins contain two N‐terminal RNA recognition motifs and play roles in posttranscriptional regulation of target mRNAs. Previously, we have identified several inhibitors of MSI1, all of which bind to MSI2 as well. In order to design MSI2‐specific inhibitors and compare the differences of binding mode of the inhibitors, we set out to solve the structure of MSI2‐RRM1, the key motif that is responsible for the binding. Here, we report the crystal structure and the first NMR solution structure of MSI2‐RRM1, and compare these to the structures of MSI1‐RBD1 and other RBPs. A high degree of structural similarity was observed between the crystal and solution NMR structures. MSI2‐RRM1 shows a highly similar overall folding topology to MSI1‐RBD1 and other RBPs. The structural information of MSI2‐RRM1 will be helpful for understanding MSI2‐RNA interaction and for guiding rational drug design of MSI2‐specific inhibitors.
Description
This work is licensed under a Creative Commons Attribution 4.0 International License.
Collections
Citation
Lan, L., Xing, M., Kashipathy, M., Douglas, J., Gao, P., Battaile, K., Hanzlik, R., Lovell, S., & Xu, L. (2020). Crystal and solution structures of human oncoprotein Musashi-2 N-terminal RNA recognition motif 1. Proteins, 88(4), 573–583. https://doi.org/10.1002/prot.25836
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.